Skip to main content

Table 1 Samples used for analysis

From: Evaluation of multi-assay algorithms for cross-sectional HIV incidence estimation in settings with universal antiretroviral treatment

Study Cohort

Sample Source

Participant group

Duration of HIV infection

# of samples

Discovery Cohort

Hormonal Contraception and HIV Genital Shedding (GS) Study

Women in Zimbabwe and Uganda (2001–2009), ART provided according to local guidelines CD4 < 250 cells/mL), prevalent subtypes A, C, and D

 < 3 months

47

3–6 months

63

6–12 months

91

12–24 months

12

2–4 years

29

4–6 years

30

6–8.7 years

38

Validation Cohort

HPTN 071 (PopART) Study

General population/household survey (2013–2018), men and women, three arm trial including early/universal ART; prevalent subtype C

 < 1 yeara

219

1–2 yearsb

208

 > 1 yearc

685

 > 2 yearsd

3483

  1. ART antiretroviral therapy
  2. aSeroconverters (infected < 1 year): HIV negative at PC12; HIV positive at PC24
  3. bNon-seroconverters (infected 1–2 years): HIV negative at PC0; HIV positive at PC12 and PC24
  4. cNon-seroconverters (infected > 1 year): HIV status unknown at PC0; HIV positive at PC12 and PC24
  5. dNon-seroconverters (infected > 2 years): HIV POS at PC0 and PC24